Author

A. Ganser

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

D. Hilfiker-Kleiner· 1 shared H. Kirchhoff· 1 shared K. Wohlan· 1 shared M. Eder· 1 shared M. Ricke-Hoch· 1 shared M. Scherr· 1 shared R. Zweigerdt· 1 shared S. Erschow· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

D. Hilfiker-Kleiner

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Targeted anti-BCR-ABL+ ALL therapy may benefit the heart

H. Kirchhoff, M. Ricke-Hoch, K. Wohlan, S. Pietzsch, U. Karsli, S. Erschow, R. Zweigerdt, A. Ganser, M. Eder, M. Scherr, D. Hilfiker-Kleiner

This paper shows that targeted therapies for BCR-ABL+ ALL can cause heart damage, but some treatments like dasatinib and venetoclax can reverse cardiac defects while others cannot.

bioRxiv · Jun 4, 2021 · PreprintCancer Biology